DrugPatentWatch Database Preview
Details for New Drug Application (NDA): 089529
NDA 089529 describes PROCAINAMIDE HYDROCHLORIDE, which is a drug marketed by Ascot, Idt Australia Ltd, Ivax Sub Teva Pharms, Lannett, Lederle, Roxane, Vangard, Watson Labs, Abraxis Pharm, Hospira, Intl Medication, Nexus Pharms, Pharmafair, Smith And Nephew, Solopak, Warner Chilcott, West-ward Pharms Int, Ani Pharms Inc, Inwood Labs, and Sandoz, and is included in fifty-eight NDAs. It is available from five suppliers. Additional details are available on the PROCAINAMIDE HYDROCHLORIDE profile page.
The generic ingredient in PROCAINAMIDE HYDROCHLORIDE is procainamide hydrochloride. There are eight drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the procainamide hydrochloride profile page.
The generic ingredient in PROCAINAMIDE HYDROCHLORIDE is procainamide hydrochloride. There are eight drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the procainamide hydrochloride profile page.
Summary for 089529
| Tradename: | PROCAINAMIDE HYDROCHLORIDE |
| Applicant: | Warner Chilcott |
| Ingredient: | procainamide hydrochloride |
| Patents: | 0 |
| Therapeutic Class: | Cardiovascular Agents |
| Formulation / Manufacturing: | see details |
Medical Subject Heading (MeSH) Categories for 089529
Profile for product number 001
| Active Rx/OTC/Discontinued: | DISCN | Dosage: | INJECTABLE;INJECTION | Strength | 500MG/ML | ||||
| Approval Date: | May 3, 1988 | TE: | RLD: | No | |||||
Complete Access Available with Subscription
